This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

SDIX And OriGene Technologies Complete Sale Of SDIX Life Science Assets To OriGene

SDIX™ (NASDAQ: SDIX) today announced it has completed the sale of the assets of its Life Science businesses to OriGene Technologies for $16 million. Following this transaction, the Company will be renamed Special Diversified Opportunities Incorporated (SDOI). OriGene Technologies is acquiring the intellectual property, current inventory and commercial contracts, as well as its equipment and will employ substantially all of the current staff. They also will acquire the rights to the SDIX branding and will conduct business as SDIX LLC.

"We are excited to combine the two companies to build one of the most comprehensive collection of high-quality antibodies for key applications both in research and diagnostics fields," said Wei-Wu He, Ph.D., Chairman and Chief Executive Officer, OriGene Technologies. "We believe the combined companies will now be better able to serve our customers with a broader portfolio of antibody products and services to help find the best solutions for their antibody and assay needs.”

Steven Becker, Chairman of the board at SDOI commented “With the transaction now closed the board of Special Diversified Opportunities Inc. will, as described in our Proxy, undertake a process to determine the best use of the company's cash, public company status and remaining assets, including net tax operating losses. We look forward to creating a beneficial result for all SDIX shareholders."

Broad Oak Capital Partners provided advisory services to SDIX for this transaction.

About OriGene Technologies ( )

OriGene Technologies, Inc. develops, manufactures, and sells genome wide research and diagnostic products worldwide. OriGene has developed an extensive array of ultra-specific monoclonal antibodies called UltraMAB™ which offers significant improvement over traditional antibodies in antibody specificity. UltraMAB™ antibodies are validated by OriGene’s proprietary high density microarray technology for a wide variety of antibody applications.

This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “can”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, our ability to determine and execute a strategy or strategies to make the best use of our cash, public company status and remaining assets, including net tax operating losses, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs